HCA Healthcare, Inc. (HCA)
NYSE: HCA · Real-Time Price · USD
303.11
-1.51 (-0.50%)
Dec 26, 2024, 9:39 AM EST - Market open
HCA Healthcare Stock Forecast
Stock Price Forecast
The 14 analysts with 12-month price forecasts for HCA Healthcare stock have an average target of 381.29, with a low estimate of 301 and a high estimate of 440. The average target predicts an increase of 25.79% from the current stock price of 303.11.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for HCA Healthcare stock from 15 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 | Dec '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 6 | 6 | 4 | 3 | 3 |
| Buy | 7 | 6 | 6 | 7 | 6 | 6 |
| Hold | 5 | 5 | 6 | 6 | 5 | 5 |
| Sell | 0 | 0 | 0 | 0 | 1 | 1 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 17 | 17 | 18 | 17 | 15 | 15 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Morgan Stanley | Morgan Stanley | Hold Maintains $406 → $355 | Hold | Maintains | $406 → $355 | +17.12% | Dec 17, 2024 |
| JP Morgan | JP Morgan | Hold Initiates $380 | Hold | Initiates | $380 | +25.37% | Dec 17, 2024 |
| Wells Fargo | Wells Fargo | Hold → Sell Downgrades $400 → $320 | Hold → Sell | Downgrades | $400 → $320 | +5.57% | Nov 25, 2024 |
| Raymond James | Raymond James | Buy → Hold Downgrades n/a | Buy → Hold | Downgrades | n/a | n/a | Nov 22, 2024 |
| Barclays | Barclays | Buy Maintains $396 → $392 | Buy | Maintains | $396 → $392 | +29.33% | Nov 8, 2024 |
Financial Forecast
Revenue This Year
71.20B
from 64.97B
Increased by 9.58%
Revenue Next Year
75.50B
from 71.20B
Increased by 6.05%
EPS This Year
22.07
from 18.97
Increased by 16.35%
EPS Next Year
24.76
from 22.07
Increased by 12.19%
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 74.6B | 80.1B | 84.8B | |||
| Avg | 71.2B | 75.5B | 79.4B | |||
| Low | 67.8B | 71.2B | 75.7B |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 14.8% | 12.5% | 12.3% | |||
| Avg | 9.6% | 6.0% | 5.2% | |||
| Low | 4.3% | -0.0% | 0.3% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 23.94 | 26.79 | 30.36 | |||
| Avg | 22.07 | 24.76 | 27.56 | |||
| Low | 20.21 | 22.94 | 24.35 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 26.2% | 21.4% | 22.6% | |||
| Avg | 16.4% | 12.2% | 11.3% | |||
| Low | 6.5% | 3.9% | -1.7% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.